Preclinical data suggest a synthetic lethal interaction between targeted ATR therapy and ARID1A deletion mutations in ovarian clear cell carcinoma and other cancer cell lines (84, 92–94). The gene discussed is ARID1A; the disease is ovarian clear cell cancer.